Pld-118 antifungal isoleucyl-tRNA synthetase inhibitor

Drugs of the Future

Volumn 27, Issue 11, 2002, Pages 1049-1055

  Sobrera, L A ^a   Castaner J ^a   Bozzo, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; ANTIFUNGAL AGENT; BETA AMINO ACID; ISOLEUCINE TRANSFER RNA LIGASE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; CANDIDA ALBICANS; COMPETITIVE INHIBITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PROTEIN SYNTHESIS INHIBITION;

EID: 0036879372     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.11.707984     Document Type: Article

References (32)

1. Mittendorf, J., Kunisch, F., Matzke, M. et al. (Bayer AG). Cyclopentane- and pentene-β-amino-acids. DE 4217776, EP 0571870, JP 1994056751.
2. Mittendorf, J., Arold, H., Fey, P., Matzke, M., Militzer, H.-C., Mohrs, K.-H. (Bayer AG). High enantio-selective process for producing pure enantiomeric cyclopentane and cyclopentene-(β)amino acids. DE 4400749, US 5962724, WO 9519337.
3. Mittendorf, J. (Bayer AG). Efficient and highly enantioselective process for the preparation of enantiomerically pure cyclopentane-β-amino acids. DE 19617772, EP 0805145, JP 1998087586, US 5877343.
4. Schoenfeld, W. Discovery, synthesis and SAR of β-amino acid BAY 10-8888/PLD-118, a novel antifungal for treatment of yeast infections. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-811.
5. Perfect, J.R. Fungal infections. Curr Opin Infect Dis 1992, 5: 433-6.
6. Beck-Sague, C., Jarvis, W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993, 167: 1247-51.
7. Wenzel, R.P. Epidemiology of nosocomial Candida infections. Infect Dis Clin Pract 1994, 3: S56-9.
8. Pittet, D., Wenzel, R.P. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155: 1177-84.
9. Pfaller, M.A. Epidemiology of candidiasis. J Hosp Infect 1995, 30: 329-38.
10. Georgopapadakou, N.H., Walsh, T.J. Human mycoses: Drugs and targets for emerging pathogens. Science 1994, 264: 371-3.
11. Odds, F.C. Editorial overview of antifungals. Curr Opin Anti-infect Invest Drug 1999, 1: 296.
12. Capobianco, J.O., Zakula, D., Coen, M.L., Goldman, R.C. Anti-Candida activity of cispentacin: The active transport by amino acid permeases and possible mechanisms of action. Biochem Biophys Res Commun 1993, 190: 1037-44.
13. Ziegelbauer, K., Babczinski, P., Schönfeld, W. Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antimicrob Agents Chemother 1998, 42: 2197-205.
14. Konishi, M., Nishio, M., Saitoh, K., Miyaki, T., Oki, T., Kawaguchi, H. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot 1989, 42: 1749-55.
15. Oki, T., Hirano, M., Tomatsu, K., Numata, K., Kamei, H. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities. J Antibiot 1989, 42: 1756-62.
16. Iwamoto, T., Tsujii, E., Ezaki, M. et al. FR109615, a new antifungal antibiotic from Streptomyces setonii. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity. J Antibiot 1990, 43: 1-7.
17. Kawabata, K., Inamoto, Y., Sakane, K., Iwamoto, T., Hashimoto, S. Synthesis and structure determination of FR109615, a new antifungal antibiotic. J Antibiot 1990, 43: 513-8.
18. Ohki, H., Inamoto, Y., Kawabata, K., Kamimura, T., Sakane, K. Synthesis and antifungal activity of FR109615 analogs. J Antibiot 1991, 44: 546-9.
19. Ziegelbauer, K., Spaltmann, F. Antifungal agents with protein biosynthesis inhibitory activity Drugs Fut 2000, 25: 63-71.
20. Ziegelbauer, K. A dual labelling method for measuring uptake of low molecular weight compounds into the pathogenic yeast Candida albicans. Med Mycol 1998, 36: 323-30.
21. Ziegelbauer, K. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic β-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 1998, 42: 1581-6.
22. Hasenoehrl, A., Skerlev, IVI., Marsic, N., Schoenfeld, W. PLD-118: A novel antifungal for treatment of yeast infections: In vitro activity against clinical isolates of Candida albicans. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst F-2143.
23. Schoenfeld, W. PLD-118: In vitro activity on Candida nonalbicans species by MIC and time-kill. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-812.
24. Schoenfeld, W., Mittendorf, J., Schmidt, A., Geschke, U. PLD-118, a novel antifungal for treatment of yeast infections: In vivo efficacy in Candida albicans infection in mice and rats. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst F-2144.
25. Schoenfeld, W., Mittendorf, J., Schmidt, A., Geschke, U., Oreskovic, K. In vivo efficacy of PLD- 118 in mice models of systemic Candida infection. 12th Eur Congr Clin Microbiol Infect Dis (April 24-27, Milan) 2002, Abst P553.
26. Petraitis, V., Petraitiene, R., Kelaher, A., Sarafandi, A., Lyman, C.A., Sein, T., Schaufele, R.L., Bacher, J., Walsh, T.J. Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthase, against experimental fluconazole-resistant, esophageal candidiasis. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-813.
27. Bogaards, J.J.P., Schut, M.W., Mildner, B., Parnham, M.J., Oreskovic, K. The novel antifungal agent PLD-118 does not inhibit cytochrome P450 enzymes in vitro. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-814.
28. Schoenfeld, W., Parnham, M. PLD-118: A novel antifungal for treatment of yeast infections: Animal pharmacokinetics. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst F-2145.
29. Oreskovic, K., Bischoff, A., Pavicic-Stedul, H., Avdagic, A., Dumic, M., KRalj, Z., Schoenfeld, W., Schroedter, A., Knoeller, J. PLD-118: Tolerability, safety and pharmacokinetics following single oral dose in healthy volunteers. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst F-2146.
30. Schroedter, A., Bischoff, A., Oreskovic, K., Knoeller, J., Schoenfeld, W., Peterson, J. PLD-118, a novel antifungal compound: Tolerabitity, safety and pharmacokinetics after multiple oral dosing in healthy male volunteers. 12th Eur Congr Clin Microbiol Infect Dis (April 24-27, Milan) 2002, Abst P1158.
31. Schroedter, A., Bischoff, A., Oreskovic, K., Knoeller, J., Radosevic, S., Schoenfeld, W., Peterson, J. A phase I multiple dose study of a novel oral antifungal PLD-118. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-815.
32. Pliva's discovery pipeline. Pliva Web Site November 28, 2002.